This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Compounder can’t shake US Lanham Act lawsuit by Novo Nordisk in Florida

By Melissa Ritti ( April 17, 2025, 18:06 GMT | Insight) -- False advertising and other claims by Novo Nordisk over compounded semaglutide aren't precluded by the Food, Drug and Cosmetic Act, a US judge ruled yesterday. Her decision draws an important distinction between IV Harmony Clinic’s conduct and that of other pharmacies that have found success in court on preemption grounds. Along the way, she delivered the Denmark-based drugmaker another win in its ongoing effort to curb unauthorized Ozempic and Wegovy sales in the US.Novo Nordisk can continue to advance its case against a Florida drug compounder it is accusing of false advertising and violations of Florida law, a US judge there ruled yesterday....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections